摘要
目的探讨达格列净对慢性心力衰竭(CHF)合并2型糖尿病(T2DM)心功能、糖代谢及肾功能及疗效的影响。方法选取2022年5月至2024年4月介休市人民医院收治的100例CHF合并T2DM患者,随机分为对照组与达格列净组,每组50例,对照组给予标准抗心力衰竭及常规降糖方案治疗,达格列净组加用达格列净治疗,治疗疗程6个月,观察治疗前后心功能、糖代谢、肾功能指标的变化及临床疗效。结果两组治疗前心功能、糖代谢、肾功能指标比较差异无统计学意义(P>0.05);左室射血分数(LVEF)治疗后高于治疗前,差异有统计学意义(P<0.05),且达格列净组高于对照组,差异有统计学意义(P<0.05);左房容积指数(LAVI)、左室舒张末期容积指数(LVEDVI)及左室收缩末期容积指数(LVESVI)、N末端B型利钠肽原(NT-ProBNP)及可溶性生长刺激表达基因2蛋白(ST2)、空腹血糖(FBG)、糖后2 h血糖(2h PG)、糖化血红蛋白(HbA1c)、肌酐(Cr)、尿酸(UA)、胱抑素C(Cys-C)水平治疗后低于治疗前,差异有统计学意义(P<0.05),且达格列净组低于对照组,差异有统计学意义(P<0.05);达格列净组总体治疗疗效优于对照组,差异有统计学意义(P<0.05)。结论达格列净对CHF合并T2DM患者的心功能、糖代谢及肾功能均有改善作用,提高了治疗疗效。
Objective To explore the effects of Dapagliflozin on cardiac function,glucose metabo⁃lism,renal function and clinical efficacy in patients with chronic heart failure(CHF)combined with type 2 dia⁃betes mellitus(T2DM).Methods A total of 100 patients with CHF combined with T2DM were randomly di⁃vided into the control group and Dapagliflozin group,with 50 patients in each group.The control group received treatment for heart failure and conventional glucose⁃lowering therapy,while the Dapagliflozin group received additional Dapagliflozin treatment.The treatment duration was 6 months.Changes in cardiac function,glucose metabolism,renal function,and oxidative stress indicators,and clinical efficacy were observed before and after treatment.Results Before treatment,there were no significant differences in cardiac function,glucose metabo⁃lism and renal function between the two groups(P>0.05).After treatment:Left ventricular ejection fraction(LVEF)was significantly higher compared to before treatment(P<0.05),and in the Dapagliflozin group showed higher LVEF than in the control group(P<0.05).Left atrial volume index(LAVI),left ventricular end⁃diastolic volume index(LVEDVI),left ventricular end⁃systolic volume index(LVESVI),N⁃terminal B⁃type natriuretic peptide(NT⁃ProBNP)and soluble suppression of tumorigenicity 2(ST2),Fasting blood glucose(FBG),2⁃hour postprandial blood glucose(2h PG)and glycosylated hemoglobin(HbA1c),Serum creatinine(Cr),uric acid(UA)and cystatin C(Cys⁃C)levels were significantly lower compared to before treatment(P<0.05),and in the Dapagliflozin group were significantly lower than in the control group(P<0.05).Overall,the therapeutic efficacy of Dagliptin group was superior to that in the control group(P<0.05).Conclusion Dapa⁃gliflozin has shown improvements in cardiac function,glucose metabolism and renal function in patients with CHF combined with T2DM.The therapeutic effect has been improved.
作者
柴红霞
范春雨
张小琴
王俊利
CHAI Hongxia;FAN Chunyu;ZHANG Xiaoqin;WANG Junli(Department of Cardiology,Jiexiu People's Hospital,Jiexiu,Shanxi,China,032000;Department of Car-diology,First Hospital of Shanxi Medical University,Taiyuan,Shanxi,China,030000;Intensive Care Medicine Department,Heji Hospital Affiliated to Changzhi Medical College,Changzhi,Shanxi,China,046000;Department of Cardiology,Heji Hospital Affiliated to Changzhi Medical College,Changzhi,Shanxi,China,046000)
出处
《分子诊断与治疗杂志》
2025年第7期1349-1351,1355,共4页
Journal of Molecular Diagnostics and Therapy
基金
晋中市科技重点研发计划(社会发展)项目(Y2240135)。
